Healthcare / BiotechnologyNasdaqCM
$1.14
+0.06 (+5.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-33.6M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$64M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-372.9%
↓Gross Margin
N/A
•Debt/Equity
1.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-34.5M · FCF $-27.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Net Income | $-34.5M | $-34.5M | $-37.6M | $-42.9M | $-40.9M | $-16.9M | $-14.8M | $-7.0M | $-3.8M | $-50.9M | $-38.8M | $-28.1M | $-12.2M | $-6.9M |
| EBITDA | $-30.3M | $-30.3M | $-33.8M | $-40.1M | $-40.7M | — | $-14.9M | $-20.9M | $-3.6M | — | — | — | — | — |
| EPS | -0.74 | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 | -0.89 | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 1.83 | 1.83 | 1.15 | 0.91 | 0.53 | — | — | — | — | — | — | 0.04 | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-27.8M | $-27.8M | $-35.1M | $-33.6M | $-25.7M | — | — | — | $-1.6M | $-40.9M | $-32.9M | $-23.1M | — | — |
| Returns | ||||||||||||||
| ROE | -372.9% | -372.9% | -197.9% | -164.3% | -92.8% | -26.8% | -54.7% | -59.8% | 185.7% | 8344.1% | -43.5% | -22.9% | 43.8% | 44.8% |
| Valuation | ||||||||||||||
| P/B | 5.72 | 5.72 | 3.45 | 5.95 | 7.40 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| EPS Growth | 28.2% | 28.2% | 25.9% | 2.8% | — | 25.8% | — | — | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.03 → -0.74
Residual
-17.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.